Axonics R20
Commercial- Indications
- Overactive bladder, Fecal incontinence, Urinary retention
Company intelligence / Profile preview
Axonics
Irvine, California, USAopenpaymentsdata.cms.gov ↗
- Ownership
- Public · AXNX
- Development stage
- Commercial
01
Overview
Axonics offers clinically proven sacral neuromodulation systems for treating urinary and bowel dysfunction. The systems, such as Axonics R20 and F15, provide long-lasting symptom relief with minimal maintenance.
- Therapeutic areas
- GastroenterologyMen's HealthNeurologyUrology
- Modalities
- Sacral Neuromodulation Systems
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Boston Scientific
04
Financials
- Market cap
- $3.6B
- Total revenue
- $116.2M
- Enterprise value
- $3.3B
Beyond the preview
Go deeper on Axonics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axonics.